Praxis Precision Medicines Provides Vormatrigine Program Update
POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure
POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.